XBP1s regulates MUC5B in a promoter variant-dependent pathway in idiopathic pulmonary fibrosis airway epithelia by Chen, G. et al.
&get_box_var;ORIGINAL ARTICLE
XBP1S Regulates MUC5B in a Promoter Variant–Dependent Pathway
in Idiopathic Pulmonary Fibrosis Airway Epithelia
Gang Chen1, Carla M. P. Ribeiro1, Ling Sun1,2, Kenichi Okuda1, Takafumi Kato1, Rodney C. Gilmore1, Mary B. Martino1,
Hong Dang1, Aiman Abzhanova1, Jennifer M. Lin1, Emily A. Hull-Ryde3, Allison S. Volmer1, Scott H. Randell1,
Alessandra Livraghi-Butrico1, Yingfeng Deng4, Philipp E. Scherer4, Barry R. Stripp5, Wanda K. O’Neal1, and
Richard C. Boucher1
1Marsico Lung Institute and Cystic Fibrosis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, North
Carolina; 2Research Center of Regeneration Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan Province,
China; 3Center of Integrative Chemical Biology and Drug Discovery, University of North Carolina Eshelman School of Pharmacy, Chapel
Hill, North Carolina; 4Department of Internal Medicine, Touchstone Diabetes Center, University of Texas Southwestern Medical Center,
Dallas, Texas; and 5Pulmonary Research, Cedars Sinai Medical Center, Los Angeles, California
ORCID ID: 0000-0001-9341-2730 (K.O.).
Abstract
Rationale: The goal was to connect elements of idiopathic pulmonary
fibrosis (IPF) pathogenesis, including chronic endoplasmic reticulum
stress in respiratory epithelia associated with injury/inflammation and
remodeling, distal airway mucus obstruction and honeycomb cyst
formationwith accumulation ofMUC5B (mucin 5B), and associations
between IPF risk and polymorphisms in theMUC5B promoter.
Objectives: To test whether the endoplasmic reticulum (ER)
stress sensor protein ERN2 (ER-to-nucleus signaling 2) and its
downstream effector, the spliced form of XBP1S (X-box–binding
protein 1), regulate MUC5B expression and differentially activate the
MUC5B promoter variant in respiratory epithelia.
Methods: Primary human airway epithelial (HAE) cells, transgenic
mouse models, human IPF lung tissues, and cell lines expressing
XBP1S andMUC5B promoters were used to explore relationships
between the ERN2/XBP1S pathway andMUC5B. An inhibitor of the
pathway, KIRA6, and XBP1 CRISPR-Cas9 were used in HAE cells to
explore therapeutic potential.
Measurements and Main Results: ERN2 regulated MUC5B
andMUC5AC mRNAs. Downstream XBP1S selectively
promoted MUC5B expression in vitro and in distal murine airway
epithelia in vivo. XBP1S bound to the proximal region of the
MUC5B promoter and differentially upregulated MUC5B
expression in the context of theMUC5B promoter rs35705950
variant. High levels of ERN2 and XBP1S were associated with
excessive MUC5B mRNAs in distal airways of human IPF lungs.
Cytokine-induced MUC5B expression in HAE cells was inhibited
by KIRA6 and XBP1 CRISPR-Cas9.
Conclusions: A positive feedback bistable ERN2–XBP1S
pathway regulates MUC5B-dominated mucus obstruction in
IPF, providing an unfolded protein response–dependent
mechanism linking theMUC5B promoter rs35705950
polymorphism with IPF pathogenesis. Inhibiting ERN2-
dependent pathways/elements may provide a therapeutic option
for IPF.
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MUC5B is the dominant gel-forming mucin
constitutively secreted by respiratory
epithelia in health and supports basal
mucociliary clearance rates and innate lung
defense (1–3). MUC5B-dominated mucus
obstruction in distal airways and
honeycomb cysts is a common feature in
idiopathic pulmonary fibrosis (IPF) (4).
The gain-of-function MUC5B promoter
variant rs35705950 is the strongest
population-wide genetic risk factor
associated with the development of IPF,
and the risk variant is linked to increased
MUC5B expression in both unaffected
and IPF subjects (4–7). However, the
mechanisms linking abnormal regulation of
MUC5B to the development of, and the role
of abnormal MUC5B expression/secretion
to distal airways disease in, IPF have not
been elucidated (6).
Endoplasmic reticulum (ER) stress,
particularly in alveolar type 2 epithelial cells
(8, 9), contributes to development of IPF in
patients that carry SFTPC (surfactant
protein C) mutations (10, 11). Interestingly,
SFTPC mutations are associated with
ectopic expression of MUC5B in alveolar
type 2–like cells and increased MUC5B
levels are observed in BAL from children
with SFTPC mutations (12), suggesting that
ER stress in alveolar type 2 or adjacent
respiratory epithelial cells is related to
increased MUC5B expression. Martino
and colleagues (13) demonstrated that the
ER stress sensor protein ERN2 (ER-to-
nucleus signaling 2), also called IRE1b
(inositol-requiring enzyme 1b), is
localized to airway mucous cells and
required for allergen-induced Muc5b and
Muc5ac expression in vivo. Similar to its
ubiquitously expressed isoform ERN1 (14),
also known as IRE1a (inositol-requiring
enzyme 1a), ERN2 contains conserved
autophosphorylating kinase domains
and distinct endoribonuclease (RNase)
domains that share 80% versus 61%
homology, respectively (15), with the
RNase dominating their functional
differences (16). A small molecule KIRA6
has been developed that attenuates ERN1
(IRE1a) RNase activity by inhibiting its
kinase domain (17).
Injury and inflammation can trigger
kinase-mediated activation of ERN1 RNase
activity (18, 19), which splices a 26-
nucleotide intron from XBP1 mRNA (20).
The spliced XBP1 (XBP1S) mRNA is
translated into a transcription factor that
regulates genes encoding ER chaperones
(21) and elements of the secretory pathway
(22), including Muc2 in the gut (23). It is,
however, unknown whether ERN2 and
XBP1S regulate mucin gene expression in
airway epithelia in normal or IPF lungs.
In this study, we tested the hypothesis
that a linkage between the unfolded protein
response (UPR) and MUC5B expression
exists that is mediated by ERN2-triggered
XBP1 splicing, which is both sufficient
and necessary for MUC5B expression.
Furthermore, we hypothesized that XBP1S
differentially regulates the MUC5B
promoter rs35705950 variant activity,
providing a potential mechanism to
generate an abnormal UPR-MUC5B
positive feedback expression cycle that
contributes to IPF pathogenesis. We also
explored whether the SPDEF (SAM pointed
domain–containing ETS transcription
factor), which regulates mucin gene
transcription (24, 25), binds to the MUC5B
promoter (26), and is expressed in IPF
goblet-like cells (27), interacted with this
pathway. A series of studies, using the
proinflammatory and profibrotic cytokine
IL-1b (28) as a tool to induce UPR-
dependent MUC5B expression in HAE cells
in vitro, recombinant cells expressing
XBP1S, and the MUC5B promoters,
transgenic mice, and freshly excised normal
and IPF lungs, were performed to test these
hypotheses.
Methods
Information about methods is available in
the online supplement.
Results
ERN2 Colocalizes with and Regulates
MUC5B and MUC5AC Expression
ERN2 regulates mucin gene expression (13),
but colocalization of ERN2 expression with
individual mucin gene expression in human
lung tissues has not been shown. ERN2
mRNA was detected in mucin secretory
cells within pseudostratified superficial
epithelia by RNAscope assays (Figures 1A
and 1B). Robust ERN2 expression was also
detected in submucosal glands (SMG)
(Figures 1C and 1D). ERN2 mRNA was
colocalized with both MUC5B and
MUC5AC in superficial epithelium and
selectively with MUC5B in SMG (Figures
1E–1H). In contrast, ERN1 mRNA was
detected in a wide variety of cell types in
superficial airway epithelia and in SMG (see
Figures E1A and E1B in the online
supplement). The localization pattern of
At a Glance Commentary
Scientific Knowledge on the
Subject: MUC5B mucin-dominated
mucus obstruction in distal airways
and honeycomb cysts likely contributes
to idiopathic pulmonary fibrosis (IPF)
pathogenesis. Consistent with this
notion, the MUC5B promoter
polymorphism (rs35705950, minor
allele “T”) is the strongest and most
replicated genetic risk factor for IPF.
What This Study Adds to the
Field: We identified a novel pathway
regulating MUC5B expression that
involves activation of a component of
the unfolded protein response (i.e., the
ERN2 [endoplasmic reticulum to
nucleus signaling 2] protein and its
downstream target, XBP1S [the spliced
form of the X-box–binding protein 1]
mRNA, which is translated into a
functional transcription factor).
XBP1S binds to the MUC5B promoter
region and induces expression of
MUC5B, but not MUC5AC, in the
distal bronchiolar epithelia in vivo and
is coexpressed with MUC5B in human
IPF lungs with excessive MUC5B
accumulation. Importantly, XBP1S
differentially activates the MUC5B
promoter carrying rs35705950 minor
allele “T,” providing a positive
feedback mechanism for unfolded
protein response–induced differential
expression of MUC5B relevant to IPF
pathogenesis/risk. Finally,
administration of a pathway inhibitor
(KIRA6) or deletion of XBP1 by
CRISPR/Cas9-mediated lentivirus
inhibited cytokine-induced mucin
biosynthesis in primary human airway
epithelial cells. This study provides
mechanistic insights into the
pathophysiology of IPF and
therapeutic approaches to reduce
mucin expression following high-
strength, irreversible activation of the
unfolded protein response in IPF.
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Figure 1. ERN2 is expressed with MUC5B and MUC5AC in mucin-secreting cells in vivo and promotes MUC5B and MUC5AC expression in human
airway epithelium in vitro. (A–H) Expression of ERN2, MUC5B, and MUC5AC mRNA was detected using RNAscope assays in pseudostratified superficial
epithelium (A, B, E, and F) and submucosal glands (C, D, G, and H) of proximal cartilaginous airways of normal adult human lung. Expression of MUC5AC
with MUC5B (A and C) and ERN1 with ERN2 (B and D) was detected by RNAscope duplex chromogenic assays. Insets show high-power view of arrow-
pointed areas. Expression of ERN2 with MUC5B (E and G) and ERN2 with MUC5AC (F and H) mRNAs was detected by RNAscope multiplex dual-
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ERN2 suggested a role in regulation of
MUC5B and MUC5AC mRNAs.
To test if ERN2 regulates
MUC5B/MUC5AC expression, primary
normal HAE cells were infected with
doxycycline (Dox)-inducible lentiviruses
expressing ERN1, ERN2, or a control
lentivirus (see Figures E1C and E1D). On
Dox administration, only ERN2 induced
MUC5B and MUC5AC mRNA expression,
although both ERN1 and ERN2 induced
mRNA expression of XBP1S and its known
target genes AGR2 (13) and DNAJB9 (29)
(Figure 1I). Neither ERN1 nor ERN2
regulated SPDEF mRNA (Figure 1I). These
results identified a specific role of ERN2,
independent of ERN1 or SPDEF, in
promoting mucin gene expression.
IL-1b Triggers UPR and Mucin Gene
Expression in Airway Epithelia
To evaluate induction of the ERN2–XBP1S
cascade in a mucus overproduction disease
context, primary HAE cells were exposed
for 24 hours to recombinant human IL-1b
(a proinflammatory/profibrotic cytokine
associated with fibrosis in mouse [30] and
human IPF [31]). IL-1b effects were
compared with the TH2 cytokine IL-13
(Figure 2). IL-13 is a key contributor to
asthma pathogenesis and MUC5AC
expression (32) and has also been
implicated in the fibrotic component of IPF
(33). Total XBP1 (XBP1T) was not different
among the treatment groups. However,
IL-1b induced mRNA expression of ERN1,
ERN2, XBP1S, and the XBP1S-regulated
UPR genes AGR2, DNAJB9, EDEM1 (34),
and HSPA5 (35) within 24 hours
(Figure 2A). In contrast, IL-13 did not
induce UPR gene expression within 24
hours (Figure 2A). IL-1b exposure over
24 hours also upregulated MUC5B and
MUC5AC mRNAs, but not the TH2-
dependent MUC5AC regulator, FOXA3
mRNA (Figure 2B). A similar profile was
observed when normal HAE cells were
exposed to another profibrotic cytokine
present in IPF lung, recombinant human
IL-17A cytokine (30, 36) for 24 hours (see
Figure E2 in the online supplement). In
contrast, IL-13 inhibited mRNA expression
of both XBP1S and MUC5B, but induced
FOXA3 (37, 38). MUC5AC mRNA was
not increased following acute IL-13
exposure for 24 hours (Figures 2A and
2B). Thus, acute induction of MUC5B
and XBP1S mRNA expression was linked
to IL-1b– and IL-17A–induced, but not IL-
13–induced, UPR signaling in primary
HAE cells.
Consistent with these findings, XBP1S
mRNA expression was weakly correlated
with MUC5B mRNA at baseline, but this
correlation became stronger after 5-day
IL-1b exposure (R2 = 0.153, P= 0.013 and
R2 = 0.527, P, 0.001 for baseline and
IL-1b, respectively) (Figure 2C). In contrast,
XBP1S expression was not correlated with
MUC5AC mRNA (R2, 0.001, P=0.998
and R2 = 0.001, P=0.864 at baseline
and after IL-1b exposure, respectively)
(Figure 2D). The strong positive correlation
of expression between XBP1S and MUC5B
mRNAs after IL-1b, coupled with the
association of the XBP1S regulator ERN2
with MUC5B expression in superficial
epithelia and SMG (Figure 1), led us to test
whether XBP1S regulated MUC5B protein
and mRNA expression.
XBP1S Differentially Regulates
MUC5B Expression In Vitro
To test whether XBP1S regulates the
secretory mucins MUC5B and MUC5AC
mRNA expression, the human bronchial
epithelial cell line BEAS2B, which expresses
low levels of endogenous MUC5B and
MUC5AC mRNAs, was transduced with a
Dox-inducible lentivirus expressing HA-
tagged XBP1S. In parallel, we expressed
HA-tagged Foxa3 in BEAS2B cells (see
Figures E3A and E3B). Heterologous
expression of XBP1S strongly induced
MUC5B and AGR2 mRNAs (Figure 3A).
Interestingly, XBP1S decreased MUC5AC
while having no effect on SPDEF mRNA
expression. In contrast, overexpression of
Foxa3 strongly induced MUC5AC, SPDEF,
and AGR2 mRNAs (Figure 3A). mRNA
expression of XBP1S regulated targets
DNAJB9, EDEM1, and HSPA5 (29) was also
strongly induced by transduced XBP1S
lentivirus (see Figure E3C). MUC5B,
MUC5AC, and AGR2 protein expression
correlated with their mRNA changes in
the cells transduced with XBP1S and
Foxa3 lentiviruses (Figure 3B). MUC5B
protein was not detected in the Foxa3
overexpressing cells by immunofluorescent
staining, although MUC5B mRNA was
modestly induced (Figures 3A and 3B).
XBP1S Regulates Muc5b Expression
in the Distal Airways In Vivo
We then tested whether the regulation of
MUC5B expression by XBP1S observed in
our in vitro studies could be detected
in vivo. Transgenic mice (Scgb1a1-rtTA
[line2] [39]/TRE-Xbp1S [40]) were
generated in which Xbp1S was condi
tionally expressed in the club cells lining
the conducting airways (39) after
administration of Dox (see Figures
E4A–E4C). In these transgenic mice, Xbp1S
mRNA was continuously induced in airway
epithelium lining both proximal and distal
airways by chronic (4-wk) Dox administration
and compared with control littermates
(TRE-Xbp1S) (Figures 4A–4D). Conditional
expression of Xbp1S did not alter Muc5b
expression in proximal airway epithelium,
as shown by immunohistochemical staining
with a Muc5b antibody (Figures 4E and
4F). However, in the distal airways,
chronic Xbp1S expression induced the
formation of Muc5b-expressing epithelial
cells (Figures 4G and 4H; see Figure E4D),
without evidence of overt pulmonary
inflammation (see Figure E4E). Muc5ac
expression was not detected in proximal
or distal airway epithelia of either
genotype (Figures 4I–4L). Muc5b
protein expression in the proximal and
distal airways in Xbp1S conditional
expression mice was quantitated by
morphometric analysis of Muc5b
Figure 1. (Continued). fluorescent assays in human cartilaginous airway epithelia. Coexpression of red and green signals in the same cell is highlighted by
white arrowheads (E–G). Micrographs in A–H are representative of n=3 lung tissue from donors without preexisting pulmonary diseases. Scale bars: A–D,
100 mm; E–H, 40 mm. (I) Doxycycline (Dox)-induced expression of ERN1 or ERN2 in primary human airway epithelia. Lentiviral stably infected human
airway epithelial cells were cultured under acute lung injury conditions for 5 days before 3-day Dox administration (250 ng/ml) in the basolateral acute lung
injury media. mRNA expression of ERN1 and ERN2; mucin-related genes MUC5B, MUC5AC, AGR2, and SPDEF; and unfolded protein response genes
XBP1S and DNAJB9 was determined by SYBR-Green quantitative (q) RT-PCR or Taqman assays. Graphs represent means6SD of n=3–4 human
airway epithelial cultures obtained from three non–cystic fibrosis/nonsmoker donors, and data were analyzed with two-way ANOVA followed by Dunnett’s
test. **P, 0.01 and ***P,0.001 compared with control subjects. NS=not significant.
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Figure 2. IL-1b induces unfolded protein response and XBP1S that is associated with MUC5B expression in human airway epithelial (HAE) cells. (A)
Unfolded protein response genes were acutely induced after IL-1b exposure. HAE cells were cultured under acute lung injury conditions for 4 weeks to
allow full differentiation before exposure with IL-1b and IL-13. Both IL-1b and IL-13 were added in basolateral acute lung injury media at 10 ng/ml for 24
hours. Expression of unfolded protein response genes XBP1T (total XBP1), ERN1, ERN2, XBP1S, AGR2, DNAJB9, EDEM1, and HSPA5 was quantified
by SYBR-green qRT-PCR or Taqman assays. (B) Expression of mucin genes MUC5B and MUC5AC and goblet cell transcription factor FOXA3 was
quantified by Taqman assay. Data are presented as mean6SE of n=1 culture of HAE cells from eight non–cystic fibrosis, nonsmoker donors, analyzed
with paired one-way ANOVA. *P,0.05 and **P, 0.01 compared with control subjects. HAE cells treated with IL-1b are labeled with green, IL-13 are
labeled with red, and control subjects are labeled with blue. (C and D) mRNA expression of XBP1S versus MUC5B (C) and XBP1S versus MUC5AC (D) in
HAE cells that were treated basolaterally with or without IL-1b 10 ng/ml (IL-1b exposure or control) for 5 days was analyzed by linear regression. The R2
and P values were compared. Normal HAE cells obtained from n=40 non–cystic fibrosis donor lungs and n=33 non–cystic fibrosis donor lungs were
tested for control and IL-1b exposure, respectively. NS=not significant.
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immunohistochemical staining volume
density, which confirmed a selective
increase in Muc5b protein expression in the
distal airways (Figure 4M). The levels of
secreted Muc5b, but not Muc5ac, protein in
BAL were also significantly increased in
Xbp1S transgenic as compared with control
mice (Figures 4N and 4O). Consistent with
the in vitro findings, overexpression of
Xbp1S did not affect Spdef expression, but
did increase expression of mucin and UPR-
related genes in the whole lung mRNA
(e.g., Clca1 [41] and Agr2) (see Figures
E4F–E4H).
XBP1S and SPDEF Are Associated
with MUC5B in the Distal Airway
Epithelia of Subjects with IPF
XBP1S and SPDEF mRNAs were associated
with MUC5AC and MUC5B protein
expression in the superficial epithelia lining
normal human cartilaginous airways (see
Figure E5A). Furthermore, the SMG of
normal human and mice, which selectively
express MUC5B protein, also expressed
XBP1S and SPDEF mRNAs (see Figures
E5A and E5B). The XBP1S/MUC5B
expression pattern matched that of ERN2 as
shown in Figures 1A–1H.
Distal airways (i.e., noncartilaginous
airways) are the most affected region by
MUC5B-dominated mucus obstruction
in IPF, and they are also the sites
exhibiting increased Muc5b expression in
Xbp1S transgenic mice. Because of the
absence of antibodies that reliably detect
expression of XBP1S and SPDEF by
immunohistochemical staining, we
applied RNAscope and Basescope to
identify these genes. IPF distal airways
from human subjects exhibited increased
MUC5B expression associated with
increased ERN2, XBP1S, and SPDEF
expression compared with control
subjects (Figure 5; see Figures E6A–E6L).
Significantly increased XBP1S and
MUC5B mRNA signal volume density in
the distal airways of IPF versus control
subjects was confirmed by morphometric
analyses (Figures 5I and 5J). Epithelial
cells within honeycomb cysts in IPF
heterogeneously expressed MUC5B,
SPDEF, ERN2, and XBP1S (see Figures
E6M–E6P vs. E6Q–E6T).
XBP1S Activates the MUC5B
Promoter and Differentially Regulates
MUC5B Expression in the Context of
the rs35705950 Variant
To further characterize MUC5B
transcriptional regulation, MUC5B
promoter–XBP1S interactions were directly
tested. Relevant to IPF pathogenesis, we
speculated that XBP1S might differentially
regulate the rs37505950 polymorphic locus
on the MUC5B promoter. SPDEF binds to
its consensus binding motif on the MUC5B
promoter in a region (23.4 to 22.7 kb)
that contains the variant locus (23.1 kb)
(26), and SPDEF mRNA is expressed in IPF
epithelia (27), suggesting it might also
regulate the MUC5B promoter and its
variant in IPF. Accordingly, we compared
XBP1S and SPDEF in the regulation of
MUC5B promoter activity, using a 4.2-kb
human MUC5B promoter (see Figure E7A)
cloned into the episomal luciferase reporter



































































































Figure 3. XBP1S regulates MUC5B expression in vitro. (A) BEAS2B cells were stably transduced with doxycycline-inducible control– (blue bars), XBP1S-
(green bars), or Foxa3- (red bars) expressing lentiviruses. Three days after doxycycline administration, mRNA expression of XBP1S, FOXA3, MUC5B,
MUC5AC, AGR2, and SPDEF was determined. Graphs represent mean6SD with n=3 independent cultures from each stably infected cell line, and data
were analyzed with one-way ANOVA followed by Dunnett’s test. (B) Immunofluorescent staining of BEAS2B cells expressing control, XBP1S, and Foxa3
(top, middle, and bottom rows, respectively). Expression of HA-tag that was fused to the N terminus of XBP1S and Foxa3 proteins is shown in the left
column with nuclei counterstained with DAPI. Dual staining of HA and MUC5B is shown in the middle column, whereas MUC5AC and AGR2 are shown in
the right column. Scale bar, 75 mm. *P, 0.05 and ***P,0.001 compared to controls.
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Figure 4. Xbp1S induces Muc5b expression in distal murine airways in vivo. (A–D) Conditional overexpression of Xbp1S mRNA (red) in the epithelium
lining from the proximal (A and B) and distal (C and D) airways in Scgb1a1-rtTA/TRE-Xbp1S transgenic mice was detected by RNA in situ hybridization
(BaseScope assay) following doxycycline food provision for 4 weeks. Doxycycline-treated littermate TRE-Xbp1S mice served as control animals. (E–H)
Cells producing Muc5b protein were detected by immunohistochemical staining with Muc5b antibodies in the epithelial cells resident from the proximal to
distal airways. (I–L) Muc5ac protein expression was detected by immunohistochemical staining with Muc5ac antibodies. Images are representative of
n=3–4 of each genotype. Scale bars: A–D, 50 mm; E–L, 100 mm. Insets show higher power views of arrow-pointed areas. (M) Quantification of Muc5b
protein expressed in mainstem bronchi versus distal airways. All distal airways with luminal diameters ,150 mm (i.e., terminal airways), regardless of
staining status, were analyzed for morphometric analyses of Muc5b immunohistochemical staining volume density in left lobes of mouse lungs (n=861.0
and n=961.8 distal airways/mouse, mean6SD, for control and Xbp1S overexpression mice, respectively). Each colored dot represents measurement
of a single airway, and each color indicates measurements obtained from a single mouse (n=5 mice of each genotype were analyzed). Data represent
mean6SD of staining volume density/distal airway in either genotype, and difference of means between the two groups (denoted by P values) were
analyzed by linear mixed-effects model with mouse identification number as random intercept variable. (N) Secretion of Muc5b and Muc5ac protein in BAL
was detected by agarose Western blot, and (O) Muc5b protein was semiquantified by densitometry. BM=basement membrane.
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Luc (carrying the major “G” allele at
rs35705950 locus). XBP1S strongly
activated the MUC5B promoter compared
with Spdef (115- vs. 2.3-fold induction,
respectively) (Figure 6A). We then
evaluated the conservation of the cis-
elements on the MUC5B promoter among
approximately 100 vertebrate species, and
found two highly conserved regions:
surrounding the rs35705950 variant
locus, and in the proximal region of the
transcription start site. Two predicted (in
silico) XBP1S binding motifs (GCCACGT)
(43, 44) were found in the 23.5-kb and
20.1-kb loci of the MUC5B promoter, with
the latter positioned in the conserved
proximal region of the MUC5B promoter
(see Figures E7B–E7E).
To test whether XBP1S physically
interacted with the MUC5B promoter, we
performed ChIP-qPCR, using the HA
antibody detecting the 3HA-Tag fused at
the N terminus of XBP1S protein (see
Figures E8A and E8B). The region
(2126/228, containing the 20.1 kb XBP1S
consensus binding motif) proximal to the
MUC5B transcription start site showed
highly enriched binding by XBP1S
compared with that of the distal region
(23552/23472, containing the 23.5-kb
putative binding sites) (10.4-fold vs. 4.2-
fold of HA/IgG ChIP-qPCR). Although
there is no XBP1S consensus binding motif
predicted adjacent to the rs35705950 locus,
XBP1S ChIP-qPCR detected enrichment of
chromatin fragments (23110/23034) in
this region compared with a nonconserved,
XBP1S-negative binding region (2937/2785)
(7.1-fold vs. 2.4-fold of HA/IgG ChIP-
qPRC, respectively) (Figures 6B and 6C).
Likewise, the promoter region of AGR2
(2540/2398), a mucin chaperon protein
(45) and a known XBP1S-regulated gene
(13), was also bound to XBP1S (see
Figure E8C).
To further evaluate these findings,
we mutated the 23.5-kb and 20.1-kb
consensus binding sites, denoted as
MUC5Bmut1 and MUC5Bmut2, respectively
(Figures 6D; see Figure E8D). Compared
with control subjects, XBP1S-induced
luciferase activity was not affected in
MUC5Bmut1, but almost completely lost
in MUC5Bmut2 (reduced by 99.5%),
whereas Spdef-induced activation was
marginally reduced in both mutants
(Figure 6E). Thus, the proximal XBP1S
binding motif located on the 20.1-kb of






































































































Figure 5. Expression of MUC5AC/MUC5B, ERN1/ERN2, XBP1S, and SPDEF mRNAs in the distal
airways of human subjects without idiopathic pulmonary fibrosis (IPF) and with IPF. (A–H) mRNA
expression of MUC5AC/MUC5B (A and B) and ERN1/ERN2 (C and D) was detected by RNAscope
Duplex assays, and XBP1S (E and F) and SPDEF (G and H) mRNAs were detected by BaseScope
assays in distal airways (,0.5 mm) of control subjects (n=4) and patients with IPF (n=8). Scale bar,
100 mm. Insets show higher power views of arrow-pointed areas. (I and J) Quantification of XBP1S (I)
and MUC5B (J) mRNA signals in the distal human airways (including all the airways with luminal
diameter ,500 mm) (i.e., terminal airways, regardless of staining status) was determined by
morphometric analysis of staining volume density detected by Basescope and RNAscope,
respectively (n=4 of control subjects and n=4 of IPF subjects). Analysis for XBP1S mRNA signal
quantification was performed with n=4.561.9 and n=4.361 distal airways/subject, mean6SD,
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MUC5B promoter activation, likely through
direct protein–DNA interaction, whereas
the distal 23.5-kb motif was dispensable.
Neither site seemed to be critically important
for Spdef-mediated activation alone
(Figure 6E).
Because SPDEF regulates MUC5B
expression and physically interacts with
MUC5B promoter region that contains
rs35705950 locus (26), and the ChIP-
qPCR showed the evidence of XBP1S
interaction with the rs35705950-
containing chromatin fragments, we
tested whether there was a synergy
between XBP1S and SPDEF to activate
the MUC5B promoter. Spdef
synergistically enhanced XBP1S
activation of the MUC5B promoter
(three to four times higher than XBP1S
alone on MUC5B[G]-Luc activity)
(Figure 6F). In contrast, XBP1S
marginally activated the MUC5AC
promoter and inhibited SPDEF-induced
MUC5AC promoter activation (see
Figure E8E).
To evaluate potential links between
XBP1S and MUC5B expression in the
context of IPF, we tested whether the
human MUC5B promoter variant
rs35705950 affected regulation by
XBP1S, Spdef, Foxa3, or by the
combination of XBP1S and Spdef.
Induction of MUC5B(T)-Luc (carrying
the minor risk “T” allele) (see Figure
E8F) by XBP1S was greater than
MUC5B(G)-Luc at all times tested (80%
higher after 3-d induction) (Figure 6G).
In contrast, there was little difference
between the two genotypes in regulation
by Foxa3 or Spdef (Figures 6G and 6H).
Spdef increased XBP1S-mediated
activation of both MUC5B(T)-Luc and
MUC5B(G)-Luc promoters (see Figure
E8G). However, because this synergy was
proportional for each genotype, this
interaction did not enhance the XBP1S
differential activation of MUC5B(T)-
Luc versus MUC5B(G)-Luc. Thus, our
data emphasize an XBP1S-dependent,
differential upregulation of the gain-of-
function rs35705950 IPF-risk variant as a
key pathway in the regulation of MUC5B
in IPF.
Loss of XBP1 Activity Inhibits MUC5B
Expression Basally and after IL-1b
Exposure
Because the ERN2/XBP1S cascade may
be a therapeutic target for mucus
obstruction dominated by MUC5B in IPF,
the use of a pharmacologic inhibitor and
CRISPR/Cas9-mediated DNA-based
approaches to interdict this regulatory
pathway were explored. Because KIRA6 is
known for its attenuation effect of ERN1
RNase activity, we tested whether KIRA6
also decreases ERN2 RNase activity
in human bronchial epithelial cells.
BEAS2B cells expressing ERN1 or
ERN2 were transfected with a XBP1
splicing-luciferase reporter (pCAX-F-
XBP1DDBD-Luc) (46), followed by
KIRA6 administration. KIRA6
moderately inhibited both ERN1- and
ERN2-activated XBP1 mRNA splicing
(see Figures E9A and E9B). Second,
administration of KIRA6 (100 nM) to
IL-1b-exposed, but not unchallenged,
HAE cells was sufficient to inhibit IL-
1b–induced XBP1 splicing and reduce
MUC5AC and MUC5B mRNA expression
without causing cytotoxicity (Figure 7A;
see Figure E9C).
We next tested whether genetic
deletion of XBP1S may also be therapeutic.
A guide RNA was designed to target the
human XBP1 gene, the precursor of XBP1S.
An XBP1 CRISPR-Cas9 (XBP1 CR)
lentivirus produced mutagenesis of
approximately 85% of the XBP1 alleles
compared with a control CRISPR (EGFP
CR) (see Figure E10) in normal HAE cells,
and XBP1CR inhibitedMUC5B mRNA and
protein expression and AGR2 and DNAJB9
mRNAs at baseline and after exposure to
IL-1b (Figures 7B and 7C). In contrast,
MUC5AC mRNA/protein and SPDEF
mRNA were not affected by the XBP1
CRISPR (Figure 7C), suggesting XBP1S
selectively regulates MUC5B expression in
a SPDEF-independent manner.
Discussion
IPF is a rapidly progressive and typically
fatal lung disease of unknown etiology.
Although therapies that slow disease
progression are available, these treatments
do not restore function and their long-term
effects on mortality are uncertain (47).
Along with the classic features of
myofibroblast differentiation, matrix
deposition, and fibroblast proliferation, the
abnormal abundance of MUC5B in the
distal IPF lung is now widely recognized.
After the strong genetic link between the
MUC5B promoter variant rs35705950 and
IPF risk was identified (4), the role of this
variant in IPF has been the focus of
research to understand the mechanisms
triggering excessive MUC5B production
and whether targeting this pathway could
be a therapeutic option for IPF.
The transcription factors SPDEF (26),
nuclear factor-kB (48, 49), and FOXA2 (7,
50) bind to both MUC5B and MUC5AC
promoters; regulate their gene expression;
and, hence, lack the specificity needed to
differentially regulate these two mucins.
The activation of XBP1S in airway
epithelial cells in in vitro and in vivomodels
(Figures 3 and 4) describes at least one
mucin selective regulatory mechanism.
Specifically, XBP1S selectively induced the
mRNA and promoter activities of MUC5B,
but not MUC5AC, in vitro (Figures 3 and
6). The coexpression of XBP1S and
MUC5B in airway epithelia of the human
lung is consistent with a regulatory
relationship between these two genes
(Figure 5; see Figures E5 and E6). Finally,
the selectivity of XBP1S for MUC5B
expression was observed in vivo in a mouse
model where selective induction of Muc5b,
but not Muc5ac, resulted from Xbp1S
overexpression driven by the Scgb1a1
promoter in mice. The mouse studies also
raised the possibility that Xbp1S-mediated
regulation of Muc5b expression dominates
in distal, not proximal, airways (Figure 4).
This notion is reinforced by previous
studies in which the same promoter driving
overexpression of Spdef (24, 25) or Foxa3
Figure 5. (Continued). for control and IPF, respectively. For MUC5B mRNA signal quantification, analysis was performed with n=3.7561.3 and
n=460.8 distal airways/subject, means6SD, for control and IPF, respectively. Each colored dot represents measurement of one airway, and each color
indicates measurements obtained from the same subject. Data represent mean6SD of signal volume density/distal airway in either group, and the
differences of means between the two groups (denoted by P values) were analyzed by linear mixed-effects model with subject identification number as
random intercept variable. BM=basement membrane.
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Figure 6. XBP1S differentially regulatesMUC5B promoter variant activity. (A) MUC5B (G)-Luc carrying “G” allele at the rs35705950 locus was transfected
into BEAS2B cells transduced with XBP1S versus control, and Spdef versus GFP lentiviruses, followed by doxycycline administration for 24 hours before
luciferase activity measurement. (B) Regions evaluated in chromatin immunoprecipitation (ChIP)-qPCR studies with the 3HA-tagged XBP1S were selected
with respect to the two predicted XBP1S consensus binding sites, the rs35705950 locus, and a negative control region (nonconserved, predicted
nonbinding) on the MUC5B promoter. (C) ChIP was performed in the BEAS2B cells transduced with control (left) or 3HA-XBP1S (right) lentiviruses using
an HA antibody or control IgG to pull down XBP1S-bound chromatin. qPCR was performed to measure the enrichment of chromatin fragments that cover
the four selected regions. Fold change of the chromatin enrichment pulled down by the HA antibody versus control IgG was compared between mean
values of two groups and labeled on top of the data from each group. Graphs present means6SD of n=3 independent experiments. (D) Two putative
conserved XBP1S binding motifs on MUC5B promoter were mutated to generate MUC5Bmut1 and MUC5Bmut2. The “G” allele was mutated to “T” at
locus of rs35705950 to generate MUC5B(T)-Luc. (E) MUC5Bmut1, MUC5Bmut2, or MUC5B(G)-Luc were transfected in BEAS2B cells expressing XBP1S
and its control, Spdef and GFP. Fold changes of promoter activity induced by XBP1S versus control, and Spdef versus GFP, were compared among three
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(51) induced goblet cell metaplasia in
proximal but not distal airways. XBP1S-
mediated increase of MUC5B expression
associated with the gain-of-function of the
MUC5B promoter variant in human distal
airways is consistent with describing
abnormal peripheral airways mucus
accumulation in human IPF lungs
(6, 52), and in a mouse model of Muc5b
overexpression in the distal lung (53). Thus,
the XBP1S regulation of MUC5B may
provide a mechanism for selective
regulation of MUC5B and a spatial
(distal vs. proximal) pattern key to IPF
pathogenesis.
The MUC5B promoter variant
rs35705950 is a gain-of-function,
expression quantitative trait locus
polymorphism. Changing the “G” to a “T”
increases MUC5B promoter activity in
A549 cells (52). Although the SPDEF (26)
and FOXA2 (7) DNA binding regions
overlap with rs35705950 locus in the
MUC5B promoter, no data are available as
to their differential regulation of the
activities of the MUC5B wild-type versus
variant promoters. In contrast, we show
that XBP1S differentially regulated MUC5B
promoter variant activity. Promoter activity
was proportionally increased when SPDEF
was coexpressed with XBP1S for each
variant. These data provide a mechanism
linking ER stress–induced activation of the
UPR transcription factor XBP1S and the
mucous cell transcription factor SPDEF to
net MUC5B promoter activity (Figure 6).
Expression of SPDEF in IPF respiratory
epithelia has been previously reported (27),
and we detected expression of both XBP1S
and SPDEF with MUC5B in distal airway
epithelia in IPF (Figures 5E–5J). This
finding is consistent with roles for XBP1S
and, to a lesser degree, SPDEF in regulating
the MUC5B promoter and its variant
activities in IPF in vivo and in vitro.
Our episomal luciferase promoter and
ChIP qPCR data indicated that the proximal
20.1-kb predicted XBP1S binding site,
but not the distal 23.5-kb predicted site,
dominates XBP1S binding and regulation
of the MUC5B promoter activity. These
data are also consistent with the presence of
highly conserved cis regulatory elements
in the proximal region of the MUC5B
promoter among approximately 100
vertebrate species (see Figures E7B and
E7E). Despite the fact that XBP1S
differentially regulates rs35705950
promoter activity, and binds to the
chromatin fragment surrounding this
variant locus (Figures 6C and 6G), there is
no predicted XBP1S binding motif in this
region. We speculate that this differential
regulation conferred by this site to MUC5B
regulation may be mediated through cis
regulatory protein–protein interactions. For
example, interactions between XBP1S and
SPDEF, the latter which physically interacts
with its binding motif in this region
(26), may contribute to the rs35705950-
dependent differential regulation of
MUC5B transcription. XBP1S and SPDEF
protein–protein interaction studies, and
XBP1S whole genome-wide ChIP-seq,
are needed to address this conjecture.
Furthermore, studies are also needed to
elucidate whether DNA methylation and/or
FOXA2, transcription factor that interacts
with a consensus binding motif adjacent
to rs35705950 locus (7), play roles in
differential XBP1S-mediated regulation of
MUC5B wild-type versus variant promoter
activities.
Upstream of XBP1S are two ER stress
sensors, ERN1 and ERN2. Different from its
role in the gut, where it suppresses the
mucin gene Muc2 (54), ERN2 increased
MUC5AC and MUC5B mRNA expression
in normal HAE cells (Figure 1I). Furthermore,
ERN2 expression correlated with MUC5B
mRNA expression in mucin-secretory cells
in the proximal airway superficial epithelia
and mucous cells in SMG (Figures 1E and
1G; see Figure E5B), suggesting a role in
regulating mucin production in health.
Although both ERN1 and ERN2 increased
XBP1S, only the ERN2–XBP1S UPR
pathway promoted mucin production. The
mechanism underlying this selectivity for
ERN2 mucin regulatory activity is unclear.
One plausible explanation is that
overexpression of ERN1 triggers an
inhibitory pathway that blocks XBP1S-
induced activation of MUC5B, perhaps
reflecting a regulated IRE1-dependent
decay of mRNA activity (55). An equally
plausible explanation is that a separate
ERN2-specific factor is required to promote
MUC5B after XBP1S induction.
Interestingly, mRNA expression of ERN2,
but not ERN1, was induced in
IPF/usual interstitial pneumonia compared
with control lung tissues (1.75-fold;
P= 83 1027) (56), suggesting that ERN2
has a unique role in development of
pulmonary fibrosis. Our detection of ERN2
mRNA in distal airways in IPF is consistent
with this notion (Figures 5C and 5D; see
Figure E6).
Our data support the model depicted
in Figure 8 of ERN2/XBP1S-mediated
regulation of MUC5B and its promoter
variant in normal and IPF distal airway
epithelia. In normal distal airway secretory
cells, we postulate that a steady-state
balance of MUC5B transcription/synthesis
is maintained by a cycle of basal MUC5B
transcription, production of MUC5B in the
ER, which triggers ERN2 activation and
XBP1S formation (Figure 8A). Note that a
positive feedback relationship characterizes
each component of this MUC5B regulatory
pathway (i.e., it is a positive feedback
system). Importantly, the positive feedback
systems can exhibit both a low stimulus
strength, low-intensity, and reversible state;
and a high stimulus strength, high-
intensity, and irreversible state (i.e., these
systems are “bistable”) (57). In response
to insults that produce injury and/or
inflammation, which accelerate MUC5B
transcription, ER stress is induced, ERN2
activated, and spliced XBP1 increases UPR
gene and MUC5B transcription rates
(Figure 8B). The signal strength of this
response is relatively small because of the
modest effect of XBP1S on regulation of
Figure 6. (Continued). luciferase vectors at 24 hours. (F) BEAS2B cells were infected with lentiviruses expressing 1) control and GFP, 2) control and Spdef,
3) XBP1S and GFP, and 4) XBP1S and Spdef. Luciferase activity was determined at 24 hours after doxycycline administration. (G) Equal amounts of
MUC5B(G)-Luc or MUC5B(T)-Luc plasmids were transfected in BEAS2B cells stably infected with control, XBP1S, and Foxa3 lentiviruses. Luciferase
activity was determined at 1, 2, and 3 days after doxycycline administration. (H) Equal quantities of MUC5B(G)-Luc and MUC5B(T)-Luc luciferase reporter
vectors were transfected into BEAS2B cells stably expressing GFP and Spdef. Cells were collected 3 days after transfection for luciferase assays. Firefly
luciferase activity was normalized to TK-Renilla (cotransfected with firefly luciferase constructs) by the dual luciferase assay; graphs present means6SD of
n=9 independent experiments, analyzed with two-tailed, unpaired t test (A, G, and H) and one-way ANOVA-Tukey test (E and F). ***P,0.001. NS=not
significant.
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Figure 7. KIRA6 and XBP1 CRISPR inhibit IL-1b–induced MUC5B expression in primary human airway epithelial (HAE) cells. (A) KIRA6 partially inhibits
XBP1S,MUC5B, andMUC5AC. Primary HAE cells were cultured under acute lung injury (ALI) condition for 4 weeks to allow full differentiation before IL-1b
exposure. At 24 hours after IL-1b (1 ng/ml in basolateral ALI media) exposure, KIRA6 was added in ALI media of the HAE cells preexposed with IL-1b at
the final concentration of 100 nM. Expression of XBP1S, MUC5B, and MUC5ACmRNAs was determined 72 hours after KIRA6 treatment by SYBR green
qRT-PCR or Taqman assays. Data represent n=1 HAE cell culture from 10 independent non–cystic fibrosis/nonsmoker donors. Data were analyzed with
two-tailed, ratio paired Student’s t test. (B) XBP1 CRISPR inhibited MUC5B expression. Primary HAE cells were stably infected with lentiviruses expressing
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MUC5B transcription in the context of the
G/G genotype. Importantly, a “small”
response is reversible on removal of the
injury/cytokine stimulus. However, the
presence of the MUC5B promoter minor
variant (carrying “G/T” or “T/T” allele)
amplifies XBP1S-induced MUC5B
transcription. This amplification produces a
high stimulus strength, reflecting a high
rate of MUC5B synthesis that may produce
an irreversible positive feedback state
(Figure 8C). This state alone may be
sufficient to trigger cellular responses
that produce impaired host defense and
accelerated cell senescence and/or damage.
In addition, the persistence of this response
may sensitize these “high-intensity” cells to
second hits with other agents (e.g., oxidant
stress), which further accentuate ER stress
and abnormal cellular responses.
One approach to turn off this positive
feedback (“vicious”) cycle is to inhibit the
ERN2/XBP1S stimulation of MUC5B
transcription. KIRA6 is a type II kinase
inhibitor that stabilizes an inactive ATP-
binding site conformation in ERN1, and
dose-dependently inhibits ERN1 kinase and
RNase activities and XBP1 splicing in vitro
and in vivo (17). We showed that KIRA6
not only inhibits ERN1-, but also ERN2-
induced XBP1 splicing in BEAS2B cells (see
Figure E9B). Because Ern2 is required for
both Muc5b and Muc5ac production
in vivo (13), we speculated that following
IL-1b exposure, KIRA6 not only would
inhibit the kinase and RNase activities of
ERN1, but likely that of ERN2, because of
their conserved kinase domain homology.
Consistent with this notion, KIRA6
inhibited IL-1b-stimulated increases in
XBP1 splicing and MUC5AC and MUC5B
mRNA expression levels in HAE cells
(Figure 7A). Suppression of IL-1b–induced
MUC5B expression likely reflected
inhibition of ERN2-mediated XBP1
splicing, whereas the reduced MUC5AC
expression was likely mediated by direct
attenuation of ERN2 activity (Figure 1I). In
these studies, IL-1b was used to generate a
cell model that mimicked the phenotypes of
IPF airway cells in terms of ER stress and
mucin overproduction. Future studies of
KIRA6 efficacy will require studies in
focused models of IPF pathogenesis.
Targeting the XBP1 gene directly
might also be a therapeutic option for
suppressing excessive MUC5B in IPF. Both
loss of function of XBP1 by CRISPR/Cas9-
mediated deletion of XBP1 and gain of
function by overexpression of Xbp1S
selectively regulated MUC5B, without
affecting MUC5AC expression (Figures 4,
7B, and 7C). Whereas MUC5B is the
dominant mucin expressed in the distal
airways of IPF lung, MUC5AC is also
basal steady state
high intensity, irreversible state
































Figure 8. A “bistable” model of ERN2/XBP1S-mediated regulation of MUC5B and its promoter
variant in distal airway epithelia of idiopathic pulmonary fibrosis. (A) Basal MUC5B transcription
producesMUC5B mRNAs that are translated into MUC5B protein at the endoplasmic reticulum (ER).
The MUC5B protein synthetic load is sensed by ERN2 (and perhaps also by ERN1), which leads to
splicing of XBP1U (unspliced XBP1) to XBP1S. XBP1S regulates basal level expression of MUC5B
and unfolded protein response (UPR) genes. Note, each step reflects a positive regulatory interaction.
(B) In a rs35705950 (G/G) distal airway mucin-secreting cell, inflammatory cytokines or other types of
injury/stimuli stimulate MUC5B expression. An increased MUC5B mRNA load fuels increased
MUC5B synthesis in ER, increased ERN2 activity, and XBP1S formation, and positive feedback by
XBP1S on MUC5B transcriptional activity. The strength of this interaction is relatively weak, reflecting
the “low-intensity state” of the XBP1S–MUC5B (G/G) promoter interaction. On removal of the stress-
causing stimuli, the cell can revert to a low MUC5B basal secretion, low UPR activation state. (C) In a
MUC5B rs35705950 (G/T or T/T) promoter distal airway mucus-secreting cell, stress signaling
triggers overloaded MUC5B mRNA and protein synthesis, which in turn leads to ERN2 hyperactivation
and increased XBP1S formation. Note, the regulatory interaction in the MUC5B promoter between
XBP1S and rs35705950 locus is amplified by the presence of G/T or T/T at that site. This positive
feedback reflects a “high-intensity state” of interaction, which produces a high-intensity signal response
that imposes significant ER stress and may be irreversible. This state is sufficient to trigger an abnormal
response to impair innate host defense and contribute to cell senescence. A second hit (e.g., oxidative
stress) may signal these already “high-intensity” cells to accentuate ER stress–induced injury further,
resulting in a profibrotic microenvironment that promotes fibroblast proliferation and myofibroblast
differentiation (not shown in the illustration).
Figure 7. (Continued). control CRISPR (EGFP CR) or XBP1 CRISPR (XBP1 CR) and cultured under ALI for 4 weeks to allow full differentiation before IL-1b
exposure (1 ng/ml). Five days after exposure with and without IL-1b, HAE cells were collected for histologic analysis, including alcian blue/periodic
acid–Schiff (AB-PAS), MUC5AC, and MUC5B immunohistochemical staining. Micrographs are representatives of lenti-CRISPR-infected HAE cells ob-
tained from three non–cystic fibrosis, nonsmoker donors. (C) Expression of MUC5B, AGR2, DNAJB9, MUC5AC, and SPDEF mRNAs in XBP1 CRISPR-
targeted cells was analyzed with Taqman assays. Graphs represent mean6SE with n=1 HAE cell culture from eight different non–cystic fibrosis,
nonsmoker donors. Data were analyzed with two-tailed, paired Student’s t test. *P, 0.05, **P,0.01, and ***P,0.001. NS=not significant.
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expressed (see Figures E6A and E6E).
Our data suggest that if modulation of
MUC5B alone is therapeutically
preferred, targeting XBP1S may be an
ideal approach. If reducing MUC5AC
is also needed, targeting SPDEF (58)
and/or ERN2 may be preferable.
In conclusion, we have demonstrated
a novel molecular mechanism for
positive regulation of MUC5B transcription
by XBP1S in airway epithelium in both
health and disease. XBP1 splicing can
be triggered by inflammatory cytokines
or other types of stimuli that trigger ER
stress (e.g., injury) (59), mediated by
ERN2 in mucin secretory cells (Figure 8).
A positive feedback cycle, particularly
in the context of the rs35705950 allele,
may provide a mechanism to generate
distal airway cells chronically expressing
a maladaptive UPR response. The
specificity of the ERN2–XBP1S pathway
to increase MUC5B expression, and its
ability to regulate MUC5B promoter
activity in a rs35705950-specific
manner, provides a rationale for
designing therapeutic approaches to
prevent and treat MUC5B-dominated
mucus hyperproduction linked to UPR
activation in pulmonary diseases, such
as IPF. n
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